黑料官网

header-logo
GettyImages-609179959-hero
headshot

Binod Dhakal, MD

Associate Professor

view physician profile

Locations

  • Froedtert Hospital
  • Clinical Cancer Center - Froedtert Hospital

Specialties

  • Hematology
  • Medical Oncology

Languages

  • English, Nepali, Hindi

Clinical Cancer Center - Froedtert Hospital

Education

  • MD - Doctor of Medicine

Biography

Binod Dhakal, MD, MS, is Assistant Professor of Medicine, at the 黑料官网, Division of Hematology, specializing in multiple myeloma and plasma cell disorders. He graduated from Manipal College of Medical Sciences, Pokhara Nepal in 2004, completed Internal Medicine Residency at Saint Francis Hospital Evanston Illinois, and a fellowship in hematology/oncology at the 黑料官网, where he also served as a Chief Fellow. Prior to joining the fellowship, he was Assistant Professor of Medicine at the Medical College in Wisconsin in the Division of General Internal Medicine. He has authored numerous publications, including journal articles, meeting abstracts and book chapters. He has also won several awards during his fellowship which include the American Society of Clinical Oncology (ASCO) Merit Award; 黑料官网 Affiliated Hospitals (黑料官网AH) research award; Central Society for Clinical and Translational Research (CSCTR) best oral abstract and travel trainee award; American Society for Blood and Marrow Transplantation (ASBMT) clinical research training course; and, Outstanding Medical School Teacher award. Additionally, he was the recipient of the Mazie Froedtert Willms and Sue Froedtert Cancer Scholarship, and obtained his Master’s Degree in Clinical and Translational Science.

Research Interests

Dr. Dhakal's current research interests focus on novel drug treatments for patients with multiple myeloma and related plasma cell disorders by designing and conducting early phase clinical trials.

Publications

  • (Yadav K, Mohan M, Wagner C, Chakraborty R, Sborov D, Godara A, McClune B, Schinke C, Dhakal B, D'Souza A, Szabo A, Mohyuddin GR.) Leukemia. 2025 Sep;39(9):2289-2291 PMID: 40670671 07/17/2025

  • (Galarza Fortuna GM, Peres LC, Nazarenko E, De Menezes Silva Corraes A, Hovanky V, Shune L, McGuirk JP, de Avila G, Khouri J, Dima D, Gaballa MR, Dhakal B, Forsberg PA, Godara A, Afrough A, Anderson LD Jr, Herr MM, Davis JA, Mann H, Purvey S, Clark WB, Htut MM, Beitinjaneh AM, Pereira DL, Kocoglu M, Ferreri CJ, Atrash S, Voorhees PM, Rossi AC, Richard S, Hashmi H, Patel KK, Sidana S, Lin Y, Hansen DK, Sborov DW.) Blood Adv. 2025 Aug 28 PMID: 40875887

  • (Vandenboom H, Akhtar O, Szabo A, Narra R, Mohan M, D'Souza A, Pasquini M, Dhakal B.) Haematologica. 2025 Aug 14 PMID: 40820831 08/18/2025

  • (Touzeau C, Lipe B, Khan AM, Dhakal B, Nair S, He J, Mendes J, Lee S, Lonardi C, Slaughter A, Lendvai N, Schecter JM, Chen D, Zhao M, Yeh TM, Leleu X, Puig N, Dytfeld D, Zamagni E, Weisel K, Karlin L, Delforge M, Corradini P, Mina R, Roeloffzen W, Sidana S.) Adv Ther. 2025 Aug 06 PMID: 40768190 08/06/2025

  • (Dhakal B, Akhtar OS, Fandrei D, Jensen A, Banerjee R, Pan D, Richard S, Friend R, Rees MJ, Costello P, Vazquez Martinez MA, Pasvolsky O, Wagner CB, Davis JA, Castaneda Puglianini OA, Reshef R, Afrough A, Dima D, Bhutani M, Nadeem O, Parrondo RD, Freeman CL, Mikkilineni L, Raza S, Anderson LD Jr, Kapoor P, Hosoya H, Chhabra S, Grajales-Cruz A, Gaballa MR, Midha S, Alsina M, Sborov DW, Patel KK, Lin Y, Ferreri CJ, Gagelmann N, Kumar AD, Hansen DK, Cowan AJ, Costa LJ, Merz M, Sidana S.) Blood. 2025 Aug 01 PMID: 40749169 08/01/2025

  • (Dhakal B, Einsele H, Schecter JM, Deraedt W, Lendvai N, Slaughter A, Lonardi C, Nair S, Varghese NE, He J, Kharat A, Lee S, Cost P, Potluri R, Koneru M, Patel N, Florendo E, Rodriguez-Otero P, Yong K.) Cancer Med. 2025 Aug;14(15):e71093 PMID: 40719208 PMCID: PMC12301936 SCOPUS ID: 2-s2.0-105011846353 07/28/2025

  • (Kasomva K, Yadav K, Janz S, Dhakal B, Rao S.) Blood Adv. 2025 Jul 17 PMID: 40674709 07/17/2025

  • (Shrestha A, Thanendrarajan S, Bag A, Dhakal B, Zangari M, Al Hadidi S, van Rhee F, D'Souza A, Shah N, Shah MR, Mohan M, Schinke C.) Blood Adv. 2025 Jul 17 PMID: 40674710 07/17/2025

  • (Jagannath S, Martin TG, Lin Y, Cohen AD, Raje N, Htut M, Deol A, Agha M, Berdeja JG, Lesokhin AM, Liegel JJ, Rossi A, Lieberman-Cribbin A, Usmani SZ, Dhakal B, Parekh S, Li H, Wang F, Montes de Oca R, Plaks V, Sun H, Banerjee A, Schecter JM, Lendvai N, Madduri D, Lengil T, Zhu J, Koneru M, Akram M, Patel N, Costa Filho O, Jakubowiak AJ, Voorhees PM.) J Clin Oncol. 2025 Jun 03:JCO2500760 PMID: 40459151 06/03/2025

  • (Mohan M, Szabo A, Cheruvalath H, Clennon A, Bhatlapenumarthi V, Patwari A, Balev M, Bhutani D, Shrestha A, Thanendrarajan S, Dhakal B, Zangari M, Trikannad A, Vellanki S, Al-Hadidi S, Lentzsch S, van Rhee F, Bag A, D'Souza A, Shah N, Chakraborty R, Shah MR, Schinke C.) Blood Cancer J. 2025 Apr 23;15(1):74 PMID: 40268898 PMCID: PMC12018942 SCOPUS ID: 2-s2.0-105003139880 04/24/2025

  • (Bal S, Magnusson T, Ravi G, Giri S, Godby K, Dhakal B, Callander NS, Silbermann RW, Dholaria B, Reddy VB, Costa LJ.) Blood Cancer J. 2025 Apr 23;15(1):73 PMID: 40268941 PMCID: PMC12019237 SCOPUS ID: 2-s2.0-105003126302 04/24/2025

  • (Henley EC, Liphart HA, Morris KJ, Awoyinka I, Irwin MR, Costanzo ES, Winston D, D'Souza A, Stolley M, Dhakal B, Mohan M, Pasquini MC, Cole SW, Doerwald ES, Bendis PC, Rentscher KE, Rumble ME, Szabo A, Rao S, Knight JM.) Contemporary Clinical Trials Communications. October 2025;47 SCOPUS ID: 2-s2.0-105013637528 10/01/2025

Publications of from the

© 2025 黑料官网.  All rights reserved.  | Terms and Privacy | Web Accessibility Statement

Non-Discrimination, Anti-Harassment, and Legal Compliance Statement
The 黑料官网 (黑料官网) is committed to fostering a diverse community of outstanding faculty, staff, and students, as well as ensuring equal educational opportunity, employment, and access to services, programs, and activities, without regard to an individual's race, color, national origin, religion, age, disability, sex, gender identity/expression, sexual orientation, marital status, pregnancy, predisposing genetic characteristic, military status, or other legally protected classification. 黑料官网 maintains full compliance with all applicable federal, state, and local laws and regulations in pursuit of our missions. Consistent with federal guidance, we affirm our commitment to individual merit, fairness, and equal treatment in all aspects of academic and institutional decision-making.

黑料官网's policies, federal and state laws, and regulations prohibit unlawful discrimination and harassment. Employees, learners, students, applicants, or other members of the 黑料官网 community (including but not limited to vendors, visitors, and guests) may not be subjected to harassment that is prohibited by law or treated adversely or retaliated against based upon a protected characteristic.